The technical and device refinements in percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) has achieved the improvement of outcome in patients with coronary artery disease (CAD). Optimal revascularization methods (PCI or CABG) for severe CAD such as multivessel and/or left main CAD is still in debate in the current clinical practice. In this review, therefore, we discuss the current status of coronary revascularization and outcome in patients with severe CAD on the basis of the evidence of clinical trials in DES era. 
I. Introduction
Coronary artery disease (CAD) is still one of the leading cause of death worldwide. Coronary revascularization as well as medical treatment is an established key treatment for both acute coronary syndrome and stable CAD over the past several decades. In this review, therefore, we discuss the current status of coronary revascularization and outcome in patients with severe CAD on the basis of the evidence of clinical trials in DES era.
II. The SYNTAX trial
The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) randomized trial is the first dedicated trial comparing PCI using first-generation DES of paclitaxel-eluting stents (PES) with CABG in patients with LM/3-vessels CAD.
3) In this trial, 1,800 patients were randomly assigned to CABG (n=897) or PCI using PES (n=903), and a composite endpoints of major adverse cardiac and cerebrovascular events (MACCE) were evaluated as a primary endpoint.
Recently published 5-year clinical follow-up results demonstrated that the cumulative incidences of MACCE (26.9% versus 37.3%, log-rank P<0.0001), myocardial infarction (MI: 3.8% versus 9.7%, log-rank P<0.0001), and repeat revascularization (13.7% versus 25.9%, log-rank P<0.0001) were significantly lower in the CABG group than in the PCI group, although those of all-cause death (11.4% versus 13.9%, log-rank P=0.10) and stroke (3.7% versus 2.4%, log-rank P=0.09) were not significantly different between the 2 groups. 
III. Multivessel disease
Several studies reported the clinical outcomes of patients with multivessel CAD after PCI as compared with those after CABG (Table 1) .
5-14)
In the 3-vessels CAD stratum of the SYNTAX trial, the cumu- randomly assigned to PCI using EES or CABG, reported that the risk of PCI with EES relative to CABG for the primary endpoint of death/MI/target-vessel revascularization was significantly higher (15.3% versus 10.6%, log-rank P=0.04).
13)
IV. Treatment selection according to anatomical complexity CAD patients with diabetes mellitus (DM) were randomly assigned to undergo PCI using DES or CABG, and reported that the primary endpoint of a composite of death/MI/stroke was significantly lower in the CABG group than in the PCI group (18.7% versus 26.6%, P=0.005).
9)
In Japan, the CREDO-Kyoto (Coronary REvascularization In the second-generation (2-G) DES era, a large-scale observational study in New York State in the United State compared (Table 2) .
17, 23-25)
In Japan, The CREDO-Kyoto registry cohort-2 reported longterm clinical outcomes after PCI and CABG in patients with LM CAD in DES era. 17) In the CREDO-Kyoto registry cohort-2, the 
V. Future perspectives in the treatment of multivessel CAD
Most previous studies showed the benefit of CABG over PCI in long-term cardiovascular outcomes even in DES era. 
VI. Left main coronary artery disease
In the LM-CAD stratum (N=705) of the SYNTAX trial, the 
VIII. Future perspectives in the treatment of LM CAD
The previous studies reporting favorable long-term clinical outcomes after PCI using DES suggest that further shifting to PCI could be possible without impairing long-term outcome in selected patients with LM CAD. The currently ongoing EXCEL trial, in which 2,600 LM CAD patients with SYNTAX score<33 randomly assign to PCI with EES or CABG, would provide further guidance for treatment for LM CAD.
IX. Conclusion
After the introduction of DES in daily clinical practice, the selection of mode of coronary revascularization has dramatically changed over time in Japan.
2) The currently available evidence based on the results of clinical studies comparing PCI with CABG in DES era suggest that CABG is still standard treatment for advanced multivessel CAD, while PCI can be a reasonable alternative to CABG in selected patients with LM CAD. More appropriate indication for coronary revascularization and selection of revascularization procedure as well as stringent adherence to evidence-based medicines might lead further improvement of outcome in patients with severe CAD.
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